keyword
MENU ▼
Read by QxMD icon Read
search

sarcoma soft tissue

keyword
https://www.readbyqxmd.com/read/27932487/mortality-risk-among-workers-with-exposure-to-dioxins
#1
J J Collins, K M Bodner, L L Aylward, T J Bender, S Anteau, M Wilken, C M Bodnar
BACKGROUND: In several studies, dioxin exposure has been associated with increased risk from several causes of death. AIMS: To compare the mortality experience of workers exposed to dioxins during trichlorophenol (TCP) and pentachlorophenol (PCP) production to that of the general population and to examine mortality risk by estimated exposure levels. METHODS: A retrospective cohort study which followed up workers' vital status from 1940 to 2011, with serum surveys to support estimation of historical dioxin exposure levels...
December 7, 2016: Occupational Medicine
https://www.readbyqxmd.com/read/27931230/feasibility-and-efficacy-of-gemcitabine-and-docetaxel-combination-chemotherapy-for-bone-and-soft-tissue-sarcomas-multi-institutional-retrospective-analysis-of-134-patients
#2
Kazuhiro Tanaka, Susumu Joyama, Hirokazu Chuman, Hiroaki Hiraga, Hideo Morioka, Hideki Yoshikawa, Masami Hosaka, Mitsuru Takahashi, Tadahiko Kubo, Hiroshi Hatano, Mitsunori Kaya, Junya Toguchida, Yoshihiro Nishida, Akihito Nagano, Hiroshi Tsumura, Yukihide Iwamoto
BACKGROUND: Bone and soft tissue sarcomas (BSTS) are rare malignant tumors. Recently, the combination of gemcitabine and docetaxel (GD) was shown to have activity as second-line setting in BSTS. However, the efficacy as first-line and adjuvant settings and precise profiles of adverse events in Japanese patients are not known yet. In the present study, the feasibility and efficacy of GD in patients with BSTS were investigated. METHODS: Patients with BSTS treated with GD in our institutions were retrospectively analyzed...
December 8, 2016: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27930525/efficacy-analysis-of-the-aprepitant-combined-antiemetic-prophylaxis-for-non-round-cell-soft-tissue-sarcoma-patients-received-adriamycin-and-ifosfamide-therapy
#3
Hitoshi Kusaba, Hozumi Kumagai, Kyoko Inadomi, Tomoya Matsunobu, Katsumi Harimaya, Kotoe Takayoshi, Shuji Arita, Hiroshi Ariyama, Koichi Akashi, Eishi Baba
Appropriate antiemetic prophylaxis for moderately emetogenic chemotherapy in patients with non-round cell soft-tissue sarcomas (NRC-STS) remains unclear. We retrospectively investigated efficacy and safety of aprepitant-combined antiemetic prophylaxis in patients with NRC-STS receiving adriamycin plus ifosfamide (AI) therapy. Forty NRC-STS patients were enrolled, their median age was 50 years (range 18-74), and 13 (32.5%) were female. Median cycle number of AI therapy was 4. Twenty patients received the doublet antiemetic prophylaxis (5-hydroxytryptamine-3 receptor antagonist and dexamethasone), and 20 received triplet (5-hydroxytryptamine-3 receptor antagonist, dexamethasone, and aprepitant)...
December 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27928478/leiomyosarcoma-of-inferior-vena-cava-and-right-atrium-with-ascites-and-jaundice-a-case-report
#4
Roshanak Hasheminasab Zavareh, Hassan Riahi Beni, Aida Iranpour, Mojgan Alam Samimi, Alireza Sadeghipour, Seyedeh Nina Alavi Niakou
Leiomyosarcoma is one of the soft tissue sarcomas that could originate from different parts of body and are mostly presented as retropritoneal mass. Leiomyosarcomas of vascular origin are particularly rare tumors occurring mainly in inferior vena cava (IVC). Here, we report the case of a 35-year-old male patient who presented with ascites and jaundice. Further evaluation revealed large hepatic and cardiac masses with extension to IVC. Since it was not possible to determine the point of origin of leiomyosarcoma, the patient received chemotherapy under diagnosis of metastatic leiomyosarcoma but unfortunately passed away...
October 1, 2016: International Journal of Hematology-oncology and Stem Cell Research
https://www.readbyqxmd.com/read/27924638/understanding-sarcomas-and-other-rare-tumors-an-interview-with-robin-l-jones
#5
Robin L Jones
Robin Jones speaks to Jade Parker, Commissioning Editor: Robin Jones is a medical oncologist specializing in the treatment of bone and soft tissue sarcomas and Head of the Sarcoma Unit at The Royal Marsden. He completed his medical training at Guy's and St Thomas' Hospital, and his oncology training at The Royal Marsden. His postgraduate research degree, with Professor Dowsett at the Institute of Cancer Research (ICR), evaluated potential predictive and prognostic factors in breast cancer patients treated with neoadjuvant chemotherapy...
December 7, 2016: Future Oncology
https://www.readbyqxmd.com/read/27922973/incidence-and-outcomes-of-dermatofibrosarcoma-protuberans-in-the-us-pediatric-population
#6
Gustavo A Rubio, Andrea Alvarado, David J Gerth, Jun Tashiro, Seth R Thaller
BACKGROUND: Dermatofibrosarcoma protuberans (DFSP) is a low-grade soft tissue sarcoma. In the pediatric population, DFSP is exceedingly rare. Aim of this study was to describe the epidemiology and clinical outcomes in a large pediatric cohort. METHODS: Surveillance, Epidemiology, and End Results (SEER) database (1973-2010) was analyzed for all patients with dermatofibrosarcoma occurring in patients <20 years of age. Data were extracted based on age, gender, race, anatomic site, histology, stage, treatment modalities, and survival...
December 5, 2016: Journal of Craniofacial Surgery
https://www.readbyqxmd.com/read/27920868/massive-localized-lymphedema-of-the-thigh-mimicking-liposarcoma
#7
Jack Porrino, Josh Walsh
Massive localized lymphedema represents a pseudosarcoma seen most commonly in middle-aged morbidly obese patients that radiologically can be easily confused for a soft-tissue sarcoma if one is not familiar with this entity. Although considered relatively rare, as the obesity epidemic continues to rise, the incidence of this entity will likely increase as well. We present a case of massive localized lymphedema occurring in the medial thigh, the most common location, with imaging and pathologic correlation.
December 2016: Radiology case reports
https://www.readbyqxmd.com/read/27920698/a-case-of-en-bloc-excision-of-a-chest-wall-leiomyosarcoma-and-closure-of-the-defect-with-non-cross-linked-collagen-matrix-egis-%C3%A2
#8
Marco Rastrelli, Saveria Tropea, Romina Spina, Alessandra Costa, Roberto Stramare, Simone Mocellin, Maria Giuseppina Bonavina, Carlo Riccardo Rossi
Sarcomas arising from the chest wall account for less than 20% of all soft tissue sarcomas, and at this site, primitive tumors are the most frequent to occur. Leiomyosarcoma is a malignant smooth muscle tumor and the best outcomes are achieved with wide surgical excision. Although advancements have been made in treatment protocols, leiomyosarcoma remains one of the more difficult soft tissue sarcoma to treat. Currently, general local control is obtained with surgical treatment with wide negative margins. We describe the case of a 50-year-old man who underwent a chest wall resection involving a wide portion of the pectoralis major and minor muscle, the serratus and part of the second, third and fourth ribs of the left side...
September 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/27920695/metastatic-alveolar-soft-part-sarcoma-responsive-to-pazopanib-after-progression-through-sunitinib-and-bevacizumab-two-cases
#9
William L Read, Felicia Williams
Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma with a propensity for lung metastases and indolent progression. ASPS is not responsive to chemotherapy, but there are case reports and small series describing benefit from drugs targeting the VEGF pathway. These drugs include sunitinib, cediranib and bevacizumab. There is no established second-line treatment for persons with ASPS progressing through first-line targeted therapy. We report two individuals with metastatic ASPS who obtained disease stabilization from sunitinib lasting over a year...
September 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/27918490/activity-of-eribulin-in-a-primary-culture-of-well-differentiated-dedifferentiated-adipocytic-sarcoma
#10
Alessandro De Vita, Giacomo Miserocchi, Federica Recine, Laura Mercatali, Federica Pieri, Laura Medri, Alberto Bongiovanni, Davide Cavaliere, Chiara Liverani, Chiara Spadazzi, Dino Amadori, Toni Ibrahim
Eribulin mesylate is a novel, non-taxane, synthetic microtubule inhibitor showing antitumor activity in a wide range of tumors including soft tissue sarcomas (STS). Eribulin has been recently approved for the treatment of metastatic liposarcoma (LPS) patients previously treated with anthracyclines. This work investigated the mechanism of action of this innovative antitubulin agent in well-differentiated/dedifferentiated LPS (ALT/DDLPS) which represents one of the most common adipocytic sarcoma histotypes. A primary culture of ALT/DDLPS from a 54-year-old patient was established...
December 3, 2016: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/27918202/treatment-of-soft-tissue-sarcoma-a-focus-on-earlier-stages
#11
Alessandro Gronchi, Robert G Maki, Robin L Jones
Surgery, with or without radiation therapy, is the standard of care for primary soft tissue sarcoma, with adjuvant/neodjuvant chemotherapy playing a role only in high-risk patients. Chemotherapy is generally the principal treatment modality for locally advanced or metastatic disease. Within this context, newer techniques and promising new treatments are challenging traditional treatment paradigms. For example, identification of histology-specific treatments is leading the field toward individualized care, with better outcomes...
January 2017: Future Oncology
https://www.readbyqxmd.com/read/27918201/the-importance-of-treating-by-histological-subtype-in-advanced-soft-tissue-sarcoma
#12
Javier Martín Broto, Axel Le Cesne, Peter Reichardt
While surgical resection (±radiotherapy) is standard treatment for localized soft tissue sarcomas (STS), chemotherapy is the mainstay for managing locally advanced and metastatic disease. Expanding knowledge of the biologies and sensitivities of STS histotypes, in conjunction with results from a growing collection of retrospective reviews and prospective randomized studies, point to the importance of treating in consideration of histological subtype. Doxorubicin ± ifosfamide continues to be standard first-line therapy for most STS subtypes...
January 2017: Future Oncology
https://www.readbyqxmd.com/read/27918200/evolution-in-soft-tissue-sarcoma
#13
Jean-Yves Blay
No abstract text is available yet for this article.
January 2017: Future Oncology
https://www.readbyqxmd.com/read/27918199/advances-and-controversies-in-the-management-of-soft-tissue-sarcomas
#14
George D Demetri, Jean-Yves Blay, Paolo G Casali
Intensive clinical research in the sarcoma field has provided insight into the histopathological diversity of soft tissue sarcomas (STS) and led to the introduction of many new agents that promise to play an important role in the management of patients with STS. While an increasing body of scientific data has advanced our knowledge of this complex family of mesenchymal diseases, several controversies remain to be resolved: Is doxorubicin-based therapy still the definitive standard first-line treatment for all patients with unresectable and/or metastatic STS of all subtypes? Is histology-driven therapy beyond gastrointestinal stromal tumors a reality or are we pursuing an unachievable objective? Are we making practical headway in the establishment of sarcoma reference centers? Is it clearly established which is the best parameter to evaluate the efficacy of a new agent in STS?...
January 2017: Future Oncology
https://www.readbyqxmd.com/read/27914772/vascular-reconstruction-after-retroperitoneal-and-lower-extremity-sarcoma-resection
#15
M Wortmann, I Alldinger, D Böckler, A Ulrich, A Hyhlik-Dürr
PURPOSE: Soft tissue sarcomas (STS) of the retroperitoneum and the lower limb with invasion of major blood vessels are very rare malignancies. This study analyses the outcome of patients with vascular replacement during resection of STS of the retroperitoneum and the lower extremity with either arterial or concomitant arterial and venous infiltration. METHODS: Patients with vascular replacement during resection of sarcoma of the retroperitoneum and the lower extremity between 1990 and 2014 were included in this retrospective single center study...
November 20, 2016: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27912995/rehabilitation-strategies-and-outcomes-of-the-sarcoma-patient
#16
REVIEW
Sean Robinson Smith
Sarcomas are a relatively rare cancer that, depending on the location, can cause significant neuromusculoskeletal dysfunction and require rehabilitation interventions to reduce pain, restore function, and improve quality of life. This review focuses on sarcoma subtypes that frequently cause these complications: bony and soft tissue sarcomas leading to limb salvage or amputation, desmoid tumors, and malignant peripheral nerve sheath tumors. Rehabilitation approaches and outcomes are discussed, as well as considerations for childhood sarcoma survivors transitioning to adulthood...
February 2017: Physical Medicine and Rehabilitation Clinics of North America
https://www.readbyqxmd.com/read/27912846/new-insights-and-evolving-role-of-pegylated-liposomal-doxorubicin-in-cancer-therapy
#17
REVIEW
Alberto A Gabizon, Yogita Patil, Ninh M La-Beck
We herein review various pharmacological and clinical aspects of pegylated liposomal doxorubicin (PLD), the first nanomedicine to be approved for cancer therapy, and discuss the gap between its potent antitumor activity in preclinical studies and its comparatively modest achievements in clinical studies and limited use in clinical practice. PLD is a complex formulation of doxorubicin based on pharmaceutical nanotechnology with unique pharmacokinetic and pharmacodynamic properties. Its long circulation time with stable retention of the payload and its accumulation in tumors with high vascular permeability both result in important advantages over conventional chemotherapy...
November 2016: Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
https://www.readbyqxmd.com/read/27909727/anti%C3%A2-proliferative-activity-of-epigallocatechin%C3%A2-3%C3%A2-gallate-and-silibinin-on-soft-tissue-sarcoma-cells
#18
Kamran Harati, Björn Behr, Christoph Wallner, Adrien Daigeler, Tobias Hirsch, Frank Jacobsen, Marcus Renner, Ali Harati, Marcus Lehnhardt, Mustafa Becerikli
Disseminated soft tissue sarcomas (STS) present a therapeutic dilemma. The first-line cytostatic doxorubicin demonstrates a response rate of 30% and is not suitable for elderly patients with underlying cardiac disease, due to its cardiotoxicity. Well‑tolerated alternative treatment options, particularly in palliative situations, are rare. Therefore, the present study assessed the anti‑proliferative effects of the natural compounds epigallocatechin-3-gallate (EGCG), silibinin and noscapine on STS cells. A total of eight different human STS cell lines were used in the study: Fibrosarcoma (HT1080), liposarcoma (SW872, T778 and MLS‑402), synovial sarcoma (SW982, SYO1 and 1273) and pleomorphic sarcoma (U2197)...
November 28, 2016: Molecular Medicine Reports
https://www.readbyqxmd.com/read/27909132/myxofibrosarcoma-of-the-extremity-and-trunk-a-multidisciplinary-approach-leads-to-good-local-rates-of-local-control
#19
C G Ghazala, N R Agni, M Ragbir, P Dildey, D Lee, K S Rankin, T B Beckingsale, C H Gerrand
AIMS: Myxofibrosarcomas (MFSs) are malignant soft-tissue sarcomas characteristically presenting as painless slowly growing masses in the extremities. Locally infiltrative growth means that the risk of local recurrence is high. We reviewed our experience to make recommendations about resection strategies and the role of the multidisciplinary team in the management of these tumours. PATIENTS AND METHODS: Patients with a primary or recurrent MFS who were treated surgically in our unit between 1997 and 2012 were included in the study...
December 2016: Bone & Joint Journal
https://www.readbyqxmd.com/read/27908980/phase-2-study-of-eribulin-in-patients-with-previously-treated-advanced-or-metastatic-soft-tissue-sarcoma
#20
Akira Kawai, Nobuhito Araki, Yoichi Naito, Toshifumi Ozaki, Hideshi Sugiura, Yasuo Yazawa, Hideo Morioka, Akihiko Matsumine, Kenichi Saito, Shun Asami, Kazuo Isu
OBJECTIVE: Eribulin, a microtubule dynamics inhibitor, is approved for the treatment of patients with breast cancer and soft tissue sarcoma. We investigated the efficacy and safety of eribulin in Japanese patients with soft tissue sarcoma. METHODS: This open-label, multicenter, nonrandomized, Phase 2 study enrolled Japanese patients with measurable, advanced/metastatic soft tissue sarcoma of high/intermediate grade and ≥1 prior chemotherapy for advanced disease...
December 1, 2016: Japanese Journal of Clinical Oncology
keyword
keyword
116948
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"